#SIckleCell
-
News
Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years
Children with sickle cell disease (SCD) as young as age 4 could be prescribed Oxbryta (Voxelotor) if the U.S. Food and Drug Administration (FDA) approves a supplemental new drug application (sNDA) submitted by…
Read More » -
TIF News
Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF
The recent population movement has led to a steady increase of carriers and patients with haemoglobin disorders, namely thalassaemia and sickle cell disease, in all countries of the European Union.…
Read More » -
Clinical News
Clinical Trials Update: The June 2021 Edition
TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
Read More » -
News
US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV
The National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation will each invest $100 million over the next four years to speed the development of affordable gene therapies for sickle cell disease (SCD)…
Read More »